Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ibandronate in Metastatic Bone Disease
NCT02564107Phase 4Completed
- Sponsor
- Roche
- Start
- Nov 2004
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ibandronic acid in metastatic bone disease (MBD), sponsored by Roche. Started Nov 2004; status: completed.
02
Drugs
ibandronic acid
03
Conditions
metastatic bone disease (MBD)
Beyond the preview
Go deeper on NCT02564107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564107.